Everolimus Tablet
Product Images NDC 0054-0480

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 0054-0480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier survival curve comparing Everolimus (N=277) and placebo (N=139) over time in months. The y-axis shows probability percentage, while the x-axis shows time in months. Everolimus shows increased survival probability over placebo, with censoring times marked. Hazard ratio is 0.33 (95% CI 0.25-0.43). Median survival times are 4.9 months for Everolimus and 1.9 months for placebo.*

FDA Label Image

Image 01

Everolimus 2.5 mg oral tablets label from Hikma Pharmaceuticals USA Inc. The label states each tablet contains 2.5 mg everolimus and includes storage instructions at 20° to 25°C (68° to 77°F). The package contains 30 tablets and displays a barcode and the labeler's location in Berkeley Heights, NJ.*

FDA Label Image

Image 02

Packaging label for Everolimus Tablets 2.5 mg by Hikma Pharmaceuticals USA Inc. The label states the dosage strength as 2.5 mg, identifies the product as tablets for oral use, and includes storage instructions to keep at 20° to 25°C and protect from light and moisture. The label features the Hikma logo and notes the product is for prescription use only.*

FDA Label Image

Image 03

Everolimus 5 mg tablets label showing dosage form and strength. The label indicates 30 oral tablets in the package and includes storage instructions, dosage guidance, and manufacturer information. Distributed by Hikma Pharmaceuticals USA Inc., the label features the product name prominently with the strength highlighted in blue and the Hikma logo in red.*

FDA Label Image

Image 04

Packaging label for Everolimus 5 mg tablets by Hikma Pharmaceuticals USA Inc. The label indicates a 28-count (4x7) unit-dose tablet package. It provides storage instructions and directs users to the package insert for complete prescribing information. The label features the Hikma logo and Rx only designation.*

FDA Label Image

Image 05

Packaging label for Everolimus tablets 7.5 mg by Hikma Pharmaceuticals USA Inc. The label indicates oral tablets with a quantity of 30 tablets. It includes usage instructions to see the package insert for dosing, storage conditions between 20° to 25°C, and a note to keep the product protected from light and out of reach of children.*

FDA Label Image

Image 06

Packaging label for Everolimus tablets, 7.5 mg strength. The label shows the product name prominently with dosage strength, and indicates that these are unit-dose tablets with a package size of 28 (4x7). The labeler is Hikma Pharmaceuticals USA Inc. Additional storage and usage instructions are visible, along with barcodes and prescription-only designation.*

FDA Label Image

Image 07

Label for Everolimus tablets 10 mg by Hikma Pharmaceuticals USA Inc. The label states it contains 30 tablets for oral use. It includes storage instructions to keep at 20° to 25°C (68° to 77°F) and protected from light and moisture, with a note to see the package insert for complete prescribing information. The label features a barcode and Rx only designation.*

FDA Label Image

Image 08

Everolimus 10 mg tablet packaging label for oral use, distributed by Hikma Pharmaceuticals USA Inc. The label indicates a 28 (4x7) unit-dose tablet count, with instructions to see the package insert for dosage information. It advises storing at 20° to 25°C in the original container, protected from light and moisture. The label includes NDC 0054-0482-14 and a red Hikma logo on the side.*

FDA Label Image

Image 09

Chemical structure of Everolimus, showing its detailed molecular components and bonds in a two-dimensional diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.